WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).

马萨诸塞州沃本（WOBURN），2024年3月14日（Global NEWSWIRE）--NeuroMetrix，Inc.（纳斯达克：NURO）注意到最近发表的一项大型研究表明，DPNCECK®联合标准心电图或DPNCECK单独可准确检测糖尿病周围神经病变（DPN）。

Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age and the coefficient of variation of R-R intervals (CVR-R), which quantifies autonomic function and is a standard output of EKG machines.

Hayashi及其同事评估了167名1型或2型糖尿病患者。DPN的参考标准是金标准神经传导研究。作者基于DPNCheck测量值，患者年龄和R-R间期变异系数（CVR-R）开发了一个预测公式，该公式量化了自主神经功能，是心电图机的标准输出。

DPNCheck combined with CVR-R had high diagnostic performance with an area under the receiver operating curve of 0.88. Similar performance was reported when using just DPNCheck to diagnose DPN. The authors concluded 'The use of DPNCheck and electrocardiogram would make the diagnosis of DPN simple, ubiquitous, and with high reproducibility and reliability.'.

DPNCECK联合CVR-R具有较高的诊断性能，受试者工作曲线下面积为0.88。仅使用DPNCheck诊断DPN时也报告了类似的性能。作者得出结论：“使用DPNCheck和心电图将使DPN的诊断变得简单，无处不在，并且具有高重复性和可靠性。”。

'This novel study by Professor Kamiya and his colleagues at the Aichi Medical University School of Medicine continues to build the large body of scientific evidence supporting the use of DPNCheck to diagnose DPN. The diagnostic accuracy of DPNCheck has now been reported in more than 10 independent published studies that evaluated over 1500 people with diabetes,' said Shai N.

爱知医科大学医学院的Kamiya教授和他的同事们的这项新研究继续建立大量科学证据，支持使用DPNCheck诊断DPN。ShaiN说，目前已有10多项独立发表的研究报告了DPNCheck的诊断准确性，这些研究评估了1500多名糖尿病患者。

Gozani, M.D., Ph.D., CEO of NeuroMetrix. 'The consistently high accuracy of DPNCheck stands in stark contrast to monofilament testing, which has been the standard approach to DPN screening despite its low accuracy and reliability. A recent large, multi-center study by Dunker and colleagues concluded 'We do not recommend the use of the 5.07/10 g monofilament in the evaluation of patients with diabetes referred to polyneuropathy assessments.'.

NeuroMetrix首席执行官戈扎尼（Gozani，M.D.，Ph.D.）说：“DPNCheck的一贯高精度与单丝测试形成鲜明对比，单丝测试是DPN筛查的标准方法，尽管其准确性和可靠性较低。Dunker及其同事最近进行的一项大型多中心研究得出结论：“我们不建议在评估多发性神经病评估的糖尿病患者时使用5.07/10 g单丝。”。

About Diabetic Peripheral Neuropathy

关于糖尿病周围神经病变

Diabetic peripheral neuropathy (DPN) is the most common long-term complication of diabetes, affecting half of people with diabetes. The clinical and economic burden of DPN stems from its central role in the development of foot ulcers that can lead to lower extremity amputation. DPN also causes debilitating chronic nerve pain and altered proprioception that increases the risk of falling, particularly in the elderly.

糖尿病周围神经病变（DPN）是糖尿病最常见的长期并发症，影响一半的糖尿病患者。DPN的临床和经济负担源于其在可能导致下肢截肢的足部溃疡发展中的核心作用。DPN还会导致衰弱的慢性神经疼痛和本体感觉改变，从而增加跌倒的风险，尤其是在老年人中。

Overall, DPN is associated with a substantial reduction in quality of life and decreased activities of daily living..

总体而言，DPN与生活质量的大幅下降和日常生活活动的减少有关。。

About DPNCheck

关于DPNCheck

DPNCheck is an automated, fast, accurate, and quantitative sural nerve conduction test used to evaluate peripheral neuropathies. It is designed to be used by clinicians at the point-of-care to detect peripheral neuropathies at an early stage when intervention is likely to be most effective, to stage the severity of nerve deterioration and to monitor disease progression and treatment benefits.

DPNCECK是一种自动化，快速，准确和定量的腓肠神经传导测试，用于评估周围神经病变。它旨在供临床医生在护理时使用，以在干预可能最有效的早期检测周围神经病变，分期神经恶化的严重程度并监测疾病进展和治疗益处。

For more information, visit dpncheck.com..

有关更多信息，请访问dpncheck.com。。

About NeuroMetrix

关于NeuroMetrix

NeuroMetrix is a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems.

NeuroMetrix是一家商业保健公司，开发和商业化神经技术设备，以解决慢性疼痛和糖尿病市场未满足的需求。该公司的产品是可穿戴或手持医疗设备，由专有耗材和软件解决方案实现，包括移动应用程序、企业软件和基于云的系统。

The Company has two commercial brands. Quell® is a wearable neuromodulation platform. DPNCheck® is a point-of-care screening test for peripheral neuropathy. For more information, visit www.neurometrix.com..

该公司有两个商业品牌。Quell®是一种可穿戴的神经调节平台。DPNCECK®是针对周围神经病变的即时筛查测试。有关更多信息，请访问www.neurometrix.com。。

Source: NeuroMetrix, Inc.

资料来源：NeuroMetrix，Inc。

Thomas T. Higgins

托马斯·T·希金斯

SVP and Chief Financial Officer

高级副总裁兼首席财务官

neurometrix.ir@neurometrix.com

neurometrix.ir@neurometrix.com